Abeona Therapeutics Advances ZEVASKYN Gene Therapy Commercialization for Rare Skin Disease
Key Insights
Abeona Therapeutics has identified 30 eligible patients for ZEVASKYN (search) gene therapy treatment at specialized centers, with 12 patients in the process of scheduling treatments for recessive dystrophic epidermolysis bullosa (search) (RDEB (search)).
Major commercial payers including UnitedHealthcare (search), Cigna, Aetna (search), Anthem (search), and most Blue Cross Blue Shield (search) plans have published policies covering ZEVASKYN (search) treatment.
The company plans to scale manufacturing capacity from current four to six monthly slots to ten slots by mid-2026, with further expansion planned by end of 2027.
Abeona Therapeutics is making significant progress in the commercial rollout of ZEVASKYN (search), its groundbreaking gene therapy for recessive dystrophic epidermolysis bullosa (search) (RDEB (search)), a rare inherited skin disorder that affects approximately 1.35 per million people. The company has identified 30 eligible patients at specialized treatment centers and secured coverage from major U.S. commercial payers.
Patient Identification and Treatment Progress
Management reported that 30 patients have been identified at qualifying treatment centers, with 12 patients "in the process of scheduling treatments" from the initial "more than a dozen" identified. This development suggests strong willingness among RDEB (search) patients to pursue the innovative treatment option.
RDEB (search) is a very rare and inherited skin disorder that leaves patients with highly sensitive skin that is easily torn or blistered. Academic studies have estimated its incidence at 3.05 per million births, with prevalence significantly lower at 1.35 per million because many sufferers die at an early age due to complications caused by this severe disorder.
Insurance Coverage and Market Access
A critical milestone for commercial success has been achieved with major insurers providing coverage commitments. Policies covering ZEVASKYN (search) have been published by all major commercial payers, including UnitedHealthcare (search), Cigna, Aetna (search), Anthem (search), and most Blue Cross Blue Shield (search) plans. The company estimates that around 60% of potential U.S. patients are already covered under these insurance plans.
The assignment of a permanent J-Code, effective January 1, 2026, represents another significant advancement that is expected to simplify billing processes for clinics administering the therapy.
Manufacturing Scale-Up Plans
To meet anticipated demand, Abeona plans to increase its monthly manufacturing capacity from the current four to six slots to ten slots by mid-2026, with further expansion envisioned by the end of 2027. Based on the U.S. population of approximately 340.1 million and the prevalence rate, there are approximately 460 potential patients in the U.S. who could benefit from ZEVASKYN (search).
Gene Therapy Mechanism
ZEVASKYN (search) is a gene therapy made from a patient's own skin, which has been modified to carry a healthy copy of a gene responsible for producing collagen, and then applied to the patient's wounds. This personalized approach represents a novel treatment strategy for patients with RDEB (search), commonly known as butterfly disease.
Financial Performance and Timeline
For the first nine months of 2025, Abeona reported a net profit of $91.64 million, primarily driven by the sale of a Priority Review Voucher (PRV) for $155 million in June 2025. Excluding this special item, the third quarter of 2025 saw a net loss of $5.2 million. The company expects to start treating patients this quarter, with significant growth in revenue anticipated in 2026.
The next quarterly report, scheduled for release between March 19 and 23, 2026, will provide crucial data on the initial commercial performance of ZEVASKYN (search), including early revenue figures and their impact on operational performance.